Showing : 1–6 of 94
Sorting out coronary stents, as time goes by.
Stefanini GG, Cutlip D.
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial
Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators.
Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach
Gheorghe Doros , PhD, Joseph M. Massaro, PhD, David E. Kandzari, MD, Ron Waksman, MD, Jacques J. Koolen, MD, Donald E. Cutlip, MD, Laura Mauri, MD, MSC
Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium
Jonathan H Seltzer MD, MA, MBA, Ted Heise, PhD, RAC, Peter Carson, MD, Daniel Canos, PhD, MPH, Jo Carol Hiatt, MD, MBA, Pascal Vranckx, MD, PhD, Thomas Christen, MD, PhD, Donald E Cutlip, MD
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, Apruzzese PK, Mauri L; Dual Antiplatelet Therapy Study Investigators.
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators.